Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Bi-partisan Senate Letter asking for 12 years of Data Protection in TPP

u.s. capitol

Senators Hatch and Kerry, along with 35 other Senators, sent a letter to Ambassador Kirk asking for 12 years of regulatory data protection consistent with U.S. law in the Trans Pacific Partnership Agreement. We are united in urging you to propose a strong minimum term of regulatory data protection for biologics consistent with U.S. law. As you are aware, U.S. law provides for a 12-year term of regulatory data protection for biologics and we believe that should serve Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Data Protection, Trans Pacific Partnership, and the US-Jordan FTA (Post 2 of 2)

Meeting

This post is a continuation of a previous post: Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2). 4.  Oxfam criticizes pharmaceutical innovators for not making all of their innovative drugs available in Jordan. Ryan responds: a.  Innovator companies introduced few new drugs before IP reform because local companies were using their know-how and clinical data to get marketing approval and brochures describing the drug’s therapeutic function and side effects Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2)

Meeting

The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements).  Organizations against the inclusion of data protection in the TPP cite as evidence an Oxfam International study titled “All Costs, No Benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.” The Oxfam paper concludes that “medicine prices have increased drastically, and TRIPS-plus rules were partly Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Non-Communicable Diseases and IP?

Flags

On September 19 and 20, the United Nations meets to potentially adopt a declaration on non-communicable diseases similar to the 2001 Declaration of Commitment on HIV/AIDS.  The diseases of particular focus include cardiovascular disease, diabetes, cancer, and respiratory disease.  Similar to previous UN initiatives around HIV/AIDS, the meeting will focus on developmental, social and economic impacts and other challenges, particularly for developing countries. UN background documents mention IP and it is possible that UN negotiations may Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Tech Transfer Summit North America

Tech Transfer Summit

The National Institutes of Health, BIO, and others are sponsoring the Tech Transfer Summit North America at NIH on 3-4 October 2011. Programming includes Translational Medicine & Funding Innovation, Successful Implementation of Biotech Innovation Strategies Worldwide, and Building Better Academia-Industry Collaborations: How will Big Pharma fill its early-stage Pipeline in 5 years’ time, among other topics. BIO’s President and CEO James C. Greenwood will give one keynote speach on the “Barriers to Innovation in biotechnology, and Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,